Telix to Host R&D Day in New York City on Sept 22, 2026
The radiopharmaceutical company will present its therapeutic and precision medicine pipeline to institutional investors and analysts.
MELBOURNE/INDIANAPOLIS — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has announced it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8.30am to 12.30pm EDT in New York City.
In a statement dated August 6, 2026, the company said institutional investors and analysts are invited to register for the in-person session, which will feature a comprehensive overview of Telix's therapeutic and precision medicine pipeline, as well as key scientific, clinical and strategic developments across the portfolio.
Members of the Telix leadership team presenting at the event include Managing Director and Group CEO Dr Christian Behrenbruch; Group Chief Medical Officer Dr David N. Cade; CEO Therapeutics Richard Valeix; CEO Precision Medicine Kevin Richardson; and Vice President Discovery Sciences Dr Michael Wheatcroft. The programme will also feature presentations by key opinion leaders offering their perspectives on the clinical and scientific opportunities.
Advance registration is required for in-person attendance, with further details including the venue, agenda and presentation materials to be provided to registered attendees. Telix noted the events are for qualified institutional investors and analysts.
The company will also host a Capital Markets Day in Melbourne on Wednesday, November 4, 2026, at which management will provide updates on strategy, growth outlook, financial targets and key business priorities. Further details will be provided in a separate announcement.
Telix is a commercial-stage global radiopharmaceutical company advancing targeted theranostics — pairing a precision diagnostic with a targeted therapy — to improve outcomes for people with cancer. Its commercial franchise is anchored by its prostate cancer imaging portfolio: Illuccix®, commercially available in 22 countries including the United States, and Gozellix®, approved by the U.S. Food and Drug Administration.
Its late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma and TLX250-Tx in kidney cancer, complemented by a pipeline of next-generation candidates.
Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America and Asia-Pacific.
This article was produced with the assistance of artificial intelligence (AI), in accordance with our editorial policy.